Stephen Strickland, Jr., MD, MSCI

Director, Leukemia Research; Chair, Leukemia Research Executive Committee, SCRI

Dr. Strickland joined Sarah Cannon Research Institute (SCRI) in 2022. In his role, he provides scientific leadership and oversees SCRI’s robust portfolio of clinical trials in leukemia, myelodysplastic syndromes, and related diseases. As chair of the Leukemia Research Executive Committee, Dr. Strickland provides oversight and develops strategy for the leukemia program. Additionally, he is an executive member of the Immune Effector Cell Therapy Research Executive Committee.

Dr. Strickland joined SCRI from Vanderbilt University Medical Center where he served as the clinical director for Acute Leukemia and the Malignant Hematology and Stem Cell Transplant medical director.

He presently serves on several leukemia related committees within the Eastern Cooperative Oncology Group and the National Comprehensive Cancer Network. Dr. Strickland received his medical degree from Louisiana State University School of Medicine and completed his internship/residency in internal medicine, clinical fellowship in hematology/oncology, and a Master of Science in clinical investigation at Vanderbilt University Medical Center.

In addition to his role with SCRI, Dr. Strickland serves as Leukemia Specialist for the Sarah Cannon Transplant & Cellular Therapy Program at TriStar Centennial.